COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
00.250.50.7511.251.51.752+Thomas (RCT)18%0.82 [0.53-1.27]recov. time48 (n)50 (n)Improvement, RR [CI]TreatmentControlZhao (PSM)72%0.28 [0.08-0.93]progression4/5512/55Tau​2 = 0.41; I​2 = 70.1%Early treatment46%0.54 [0.19-1.51]4/10312/10546% improvementKrishnan31%0.69 [0.47-0.92]death40/7952/73Improvement, RR [CI]TreatmentControlZhang (RCT)50%0.50 [0.20-1.50]death6/2711/29Patel29%0.71 [0.43-1.14]death22/9626/80Kumari (RCT)36%0.64 [0.26-1.55]death7/7511/75Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1JamaliMog.. (RCT)0%1.00 [0.22-4.56]death3/303/30Gao86%0.14 [0.03-0.72]death1/465/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]death5/409/40CT​1Al Sulaiman (PSM)15%0.85 [0.61-1.12]death46/14259/142Gadhiya-1%1.01 [0.48-1.91]death19/5536/226Hakamifard (RCT)46%0.54 [0.14-2.08]ICU3/385/34CT​1Suna21%0.79 [0.44-1.41]death17/15324/170Li (PSM)-11%1.11 [0.79-1.54]death7/819/24Özgünay9%0.91 [0.63-1.30]death17/3275/128Tau​2 = 0.00; I​2 = 0.0%Late treatment19%0.81 [0.71-0.93]195/831338/1,09119% improvementBehera10%0.90 [0.63-1.21]cases29/67157/305Improvement, RR [CI]TreatmentControlLouca0%1.00 [0.97-1.04]casesTau​2 = 0.00; I​2 = 0.0%PrEP0%1.00 [0.97-1.03]29/67157/3050% improvementAll studies15%0.85 [0.75-0.96]228/1,001507/1,50115% improvement18 vitamin C COVID-19 studiesc19vitaminc.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.02; I​2 = 37.0%; Z = 2.62Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Krishnan31%0.69 [0.47-0.92]40/7952/73Improvement, RR [CI]TreatmentControlZhang (RCT)50%0.50 [0.20-1.50]6/2711/29Patel29%0.71 [0.43-1.14]22/9626/80Kumari (RCT)36%0.64 [0.26-1.55]7/7511/75JamaliMog.. (RCT)0%1.00 [0.22-4.56]3/303/30Gao86%0.14 [0.03-0.72]1/465/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]5/409/40CT​1Al Sulaiman (PSM)15%0.85 [0.61-1.12]46/14259/142Gadhiya-1%1.01 [0.48-1.91]19/5536/226Suna21%0.79 [0.44-1.41]17/15324/170Li (PSM)-11%1.11 [0.79-1.54]7/819/24Özgünay9%0.91 [0.63-1.30]17/3275/128Tau​2 = 0.00; I​2 = 1.4%Late treatment18%0.82 [0.72-0.93]190/783330/1,04718% improvementAll studies18%0.82 [0.72-0.93]190/783330/1,04718% improvement12 vitamin C COVID-19 mortality resultsc19vitaminc.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 1.4%; Z = 2.95Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Darban (RCT)6%0.94 [0.84-1.06]10 (n)10 (n)CT​1Improvement, RR [CI]TreatmentControlHakamifard (RCT)46%0.54 [0.14-2.08]3/385/34CT​1Suna-2%1.02 [0.46-2.24]11/15312/170Tau​2 = 0.00; I​2 = 0.0%Late treatment6%0.94 [0.84-1.05]14/20117/2146% improvementAll studies6%0.94 [0.84-1.05]14/20117/2146% improvement3 vitamin C COVID-19 ICU resultsc19vitaminc.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 1.10Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Kumari (RCT)24%0.76 [0.66-0.87]hosp. time75 (n)75 (n)Improvement, RR [CI]TreatmentControlJamaliMog.. (RCT)-31%1.31 [1.03-1.66]hosp. time30 (n)30 (n)Hamidi-Ala.. (RCT)38%0.62 [0.45-0.86]hosp. time40 (n)40 (n)CT​1Hakamifard (RCT)1%0.99 [0.91-1.07]hosp. time38 (n)34 (n)CT​1Tau​2 = 0.05; I​2 = 87.7%Late treatment10%0.90 [0.71-1.13]0/1830/17910% improvementAll studies10%0.90 [0.71-1.13]0/1830/17910% improvement4 vitamin C COVID-19 hospitalization resultsc19vitaminc.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.05; I​2 = 87.7%; Z = 0.91Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Zhao (PSM)72%0.28 [0.08-0.93]progression4/5512/55Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment72%0.28 [0.08-0.93]4/5512/5572% improvementKrishnan31%0.69 [0.47-0.92]death40/7952/73Improvement, RR [CI]TreatmentControlZhang (RCT)50%0.50 [0.20-1.50]death6/2711/29Patel29%0.71 [0.43-1.14]death22/9626/80Kumari (RCT)36%0.64 [0.26-1.55]death7/7511/75Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1JamaliMog.. (RCT)0%1.00 [0.22-4.56]death3/303/30Gao86%0.14 [0.03-0.72]death1/465/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]death5/409/40CT​1Al Sulaiman (PSM)15%0.85 [0.61-1.12]death46/14259/142Gadhiya-1%1.01 [0.48-1.91]death19/5536/226Hakamifard (RCT)46%0.54 [0.14-2.08]ICU3/385/34CT​1Suna21%0.79 [0.44-1.41]death17/15324/170Li (PSM)-11%1.11 [0.79-1.54]death7/819/24Özgünay9%0.91 [0.63-1.30]death17/3275/128Tau​2 = 0.00; I​2 = 0.0%Late treatment19%0.81 [0.71-0.93]195/831338/1,09119% improvementAll studies20%0.80 [0.69-0.92]199/886350/1,14620% improvement15 vitamin C COVID-19 serious outcomesc19vitaminc.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.01; I​2 = 8.9%; Z = 3.12Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Behera10%0.90 [0.63-1.21]29/67157/305Improvement, RR [CI]TreatmentControlLouca0%1.00 [0.97-1.04]Tau​2 = 0.00; I​2 = 0.0%PrEP0%1.00 [0.97-1.03]29/67157/3050% improvementAll studies0%1.00 [0.97-1.03]29/67157/3050% improvement2 vitamin C COVID-19 case resultsc19vitaminc.com Aug 29, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.07Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Zhao (PSM)-8%1.08 [0.64-1.80]55 (n)55 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment-8%1.08 [0.64-1.80]0/550/55-8% improvementAll studies-8%1.08 [0.64-1.80]0/550/55-8% improvement1 vitamin C COVID-19 viral clearance resultc19vitaminc.com Aug 29, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.28Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Thomas (RCT)18%0.82 [0.53-1.27]recov. time48 (n)50 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment18%0.82 [0.53-1.27]0/480/5018% improvementZhang (RCT)50%0.50 [0.20-1.50]death6/2711/29Improvement, RR [CI]TreatmentControlKumari (RCT)36%0.64 [0.26-1.55]death7/7511/75Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1JamaliMog.. (RCT)0%1.00 [0.22-4.56]death3/303/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]death5/409/40CT​1Hakamifard (RCT)46%0.54 [0.14-2.08]ICU3/385/34CT​1Tau​2 = 0.00; I​2 = 0.0%Late treatment41%0.59 [0.38-0.93]26/22042/21841% improvementAll studies30%0.70 [0.51-0.96]26/26842/26830% improvement7 vitamin C COVID-19 Randomized Controlled Trialsc19vitaminc.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.24Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Zhang (RCT)50%0.50 [0.20-1.50]6/2711/29Improvement, RR [CI]TreatmentControlKumari (RCT)36%0.64 [0.26-1.55]7/7511/75JamaliMog.. (RCT)0%1.00 [0.22-4.56]3/303/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]5/409/40CT​1Tau​2 = 0.00; I​2 = 0.0%Late treatment41%0.59 [0.36-0.98]21/17234/17441% improvementAll studies41%0.59 [0.36-0.98]21/17234/17441% improvement4 vitamin C COVID-19 RCT mortality resultsc19vitaminc.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 2.06Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Thomas (RCT)18%0.82 [0.53-1.27]recov. time48 (n)50 (n)Improvement, RR [CI]TreatmentControlZhao (PSM)72%0.28 [0.08-0.93]progression4/5512/55Tau​2 = 0.41; I​2 = 70.1%Early treatment46%0.54 [0.19-1.51]4/10312/10546% improvementKrishnan31%0.69 [0.47-0.92]death40/7952/73Improvement, RR [CI]TreatmentControlZhang (RCT)50%0.50 [0.20-1.50]death6/2711/29Patel29%0.71 [0.43-1.14]death22/9626/80Kumari (RCT)36%0.64 [0.26-1.55]death7/7511/75Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1Gao86%0.14 [0.03-0.72]death1/465/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]death5/409/40CT​1Gadhiya-1%1.01 [0.48-1.91]death19/5536/226Hakamifard (RCT)46%0.54 [0.14-2.08]ICU3/385/34CT​1Suna21%0.79 [0.44-1.41]death17/15324/170Li (PSM)-11%1.11 [0.79-1.54]death7/819/24Özgünay9%0.91 [0.63-1.30]death17/3275/128Tau​2 = 0.00; I​2 = 3.6%Late treatment20%0.80 [0.69-0.93]146/659276/91920% improvementBehera10%0.90 [0.63-1.21]cases29/67157/305Improvement, RR [CI]TreatmentControlLouca0%1.00 [0.97-1.04]casesTau​2 = 0.00; I​2 = 0.0%PrEP0%1.00 [0.97-1.03]29/67157/3050% improvementAll studies16%0.84 [0.73-0.96]179/829445/1,32916% improvement16 vitamin C COVID-19 peer reviewed trialsc19vitaminc.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.02; I​2 = 42.6%; Z = 2.50Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Thomas (RCT)18%0.82 [0.53-1.27]recov. time48 (n)50 (n)Improvement, RR [CI]TreatmentControlZhao (PSM)72%0.28 [0.08-0.93]progression4/5512/55Zhao (PSM)-8%1.08 [0.64-1.80]viral time55 (n)55 (n)Krishnan31%0.69 [0.47-0.92]death40/7952/73Zhang (RCT)50%0.50 [0.20-1.50]death6/2711/29Zhang (RCT)80%0.20 [0.10-0.90]death5/2711/29Zhang (RCT)50%0.50 [0.20-1.80]death6/2710/29Zhang (RCT)70%0.30 [0.21-1.10]death5/2710/29Patel29%0.71 [0.43-1.14]death22/9626/80Patel16%0.84 [0.52-1.36]death15/3016/27Kumari (RCT)36%0.64 [0.26-1.55]death7/7511/75Kumari (RCT)20%0.80 [0.40-1.59]ventilation12/7515/75Kumari (RCT)26%0.74 [0.64-0.86]recov. time75 (n)75 (n)Kumari (RCT)24%0.76 [0.66-0.87]hosp. time75 (n)75 (n)Darban (RCT)33%0.67 [0.14-3.17]progression2/103/10CT​1Darban (RCT)6%0.94 [0.84-1.06]ICU10 (n)10 (n)CT​1JamaliMog.. (RCT)0%1.00 [0.22-4.56]death3/303/30JamaliMog.. (RCT)-25%1.25 [0.37-4.21]ventilation5/304/30JamaliMog.. (RCT)-31%1.31 [1.03-1.66]hosp. time30 (n)30 (n)Gao86%0.14 [0.03-0.72]death1/465/30Hamidi-Ala.. (RCT)44%0.56 [0.20-1.51]death5/409/40CT​1Hamidi-Ala.. (RCT)38%0.62 [0.45-0.86]hosp. time40 (n)40 (n)CT​1Al Sulaiman (PSM)15%0.85 [0.61-1.12]death46/14259/142Gadhiya-1%1.01 [0.48-1.91]death19/5536/226Hakamifard (RCT)46%0.54 [0.14-2.08]ICU3/385/34CT​1Hakamifard (RCT)1%0.99 [0.91-1.07]hosp. time38 (n)34 (n)CT​1Suna21%0.79 [0.44-1.41]death17/15324/170Suna-2%1.02 [0.46-2.24]ICU11/15312/170Li (PSM)-11%1.11 [0.79-1.54]death7/819/24Özgünay9%0.91 [0.63-1.30]death17/3275/128Özgünay-1%1.01 [0.79-1.29]ventilation23/3291/128Behera10%0.90 [0.63-1.21]cases29/67157/305Behera17%0.83 [0.58-1.11]cases29/67157/305Louca0%1.00 [0.97-1.04]casesvitamin C COVID-19 outcomesc19vitaminc.com Aug 29, 2021Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home